Brief: Actinium Highlights First-In-Class Her3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity Of In Ovarian And Colorectal Cancer Models At The AACR Annual Meeting
19/04/2023 13:47
April 19 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM HIGHLIGHTS FIRST-IN-CLASS HER3 TARGETED
RADIOTHERAPY
DATA DEMONSTRATING POTENT ANTI-CANCER ACTIVITY OF IN OVARIAN AND
COLORECTAL CANCER MODELS AT THE AACR ANNUAL MEETING
Source text for Eikon: ID:nPn9w29S5a
Further company coverage: ATNM.A
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities